



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

02nd September, 2016

Corporate Relationship Department
M/s.BSE Limited
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) **Mumbai 400 051**

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/09/2016

Press Release

NATCO's marketing partner Mylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding

Hyderabad, India, September 2nd, 2016

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced that the U.S. Patent and Trademark Office (PTO) has ruled in favor of its marketing partner, Mylan, in its inter partes review (IPR) proceeding and found all claims of U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd., unpatentable. This is the third patent related to Copaxone® 40 mg/mL to be found unpatentable in the last week.

On August, 24, 2016 the PTO's Patent Trial and Appeal Board (PTAB) found Teva's first two patents, U.S. Patent Nos. are 8,232,250 and 8,399,413, unpatentable in Mylan's IPR challenge of these patents.

NATCO's marketing partner Mylan believes it is one of the first companies to have filed a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for a three times per week Glatiramer Acetate Injection 40 mg/mL, and expects to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval.

Copaxone® 40 mg/mL had U.S. sales of approximately \$3.3 billion for the 12 months ending June 30, 2016, according to IMS Health.

Forwarded for favour of publication

For NATCO Pharma Limited

M. Adinarayana

M. Adinarayana

Company Secretary &

Vice President (Legal and Corp. Affairs)